Park National Corp OH Trims Stock Holdings in Danaher Co. (NYSE:DHR)

Park National Corp OH cut its stake in shares of Danaher Co. (NYSE:DHR) by 1.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 83,323 shares of the conglomerate’s stock after selling 1,497 shares during the quarter. Park National Corp OH’s holdings in Danaher were worth $19,127,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Teachers Insurance & Annuity Association of America purchased a new position in Danaher during the third quarter valued at approximately $39,000. MidAtlantic Capital Management Inc. bought a new stake in shares of Danaher during the 3rd quarter valued at $40,000. FSA Wealth Management LLC purchased a new position in shares of Danaher during the 3rd quarter valued at $50,000. Darwin Wealth Management LLC bought a new position in Danaher in the 3rd quarter worth $55,000. Finally, Dunhill Financial LLC increased its stake in Danaher by 45.1% in the 3rd quarter. Dunhill Financial LLC now owns 222 shares of the conglomerate’s stock worth $62,000 after buying an additional 69 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently commented on DHR shares. Stephens restated an “overweight” rating and issued a $315.00 price objective on shares of Danaher in a research report on Wednesday, October 23rd. Raymond James dropped their price target on Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Citigroup reduced their price objective on shares of Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a research report on Monday. Guggenheim started coverage on shares of Danaher in a research report on Thursday, December 19th. They set a “buy” rating and a $275.00 target price for the company. Finally, KeyCorp lifted their price target on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $286.80.

Danaher Price Performance

NYSE:DHR opened at $239.00 on Wednesday. The firm has a market capitalization of $172.62 billion, a price-to-earnings ratio of 45.61, a PEG ratio of 4.33 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The business has a 50 day simple moving average of $236.17 and a 200-day simple moving average of $254.11. Danaher Co. has a 1 year low of $222.53 and a 1 year high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same period in the previous year, the firm earned $2.02 earnings per share. Danaher’s quarterly revenue was up 3.1% compared to the same quarter last year. Equities analysts forecast that Danaher Co. will post 7.5 EPS for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is currently 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.